PRESS RELEASE: EORTC and ESTRO announce E2-RADIatE platform’s first site activation for Oligometastatic Disease

Brussels, Belgium: European Organisation for Research and Treatment of Cancer (EORTC) and European Society for Radiotherapy and Oncology (ESTRO) announces the first site activation for the E2-RADIatE platform.

E2-RADIatE is a platform built to host prospective data registries of “real-world” data on patients treated with radiotherapy.  Radiation therapy still suffers from a lack of collective knowledge on how treatments affect patient’s survival and quality of life. For a number of cancers and indications, information is available through clinical trials but formal data collection and data sharing is rather random especially with new treatments and techniques, possibly resulting in patients not receiving the best treatment for their cancer.

The platform will link diagnostic, radiation imaging, and treatment data to clinical outcomes for a number of cancers, thereby facilitating the analysis of new clinical indications treated with radiotherapy and the monitoring of new radiation techniques and technologies.

“This joint development of a holistic database and infrastructure for radiation oncology research is in line with the ESTRO Vision 2030,” says Professor Yolande Lievens, ESTRO Past-President and E2-RADIatE Study Coordinator.

OligoCare is the first project hosted on the E2-RADIatE platform that will collect data on the treatment of oligometastatic disease in lung, breast, prostate and colorectal cancer. The objective of this data collection is to identify what factors (cancer, organ affected, staging, treatment) have an impact on overall survival of patients who develop oligometastatic disease at some point.

The site of Dr. Yannick Neybuch (Hôpital de Jolimont, Haine St Paul, Belgium) is the first of 29 centres in 5 countries to be activated for E²-RADIatE, to start recruiting patients for OligoCare. It is anticipated that more centres and countries will follow in the coming years.

“The E2-RADIatE platform will serve as an umbrella collecting real-world data to support radiotherapy”, says Ellen Peeters, EORTC Project Manager E2-RADIatE. “It fits within the strategy of EORTC to conduct multidisciplinary research covering all aspects of cancer management.”

EORTC and ESTRO partnership endeavours to use this overarching platform to address the needs of the radiation oncology community in understanding the effectiveness of new and innovative treatments in improving the quality of life and survival of cancer patients.

“Understanding what is happening in the real world will provide tremendous insights on best treatment for better care,” says Professor Damien Weber, Chair of the EORTC Radiation Oncology Group. “We encourage other centres to engage in this platform.”


About EORTC (European Organisation for Research and Treatment of Cancer)

The EORTC brings together European clinical cancer research experts from all disciplines for collaboration in clinical trials. Both multinational and multidisciplinary, the EORTC Network comprises more than 5,000 collaborators from all disciplines involved in cancer treatment and research in more than 900 hospitals and institutions in over 35 countries. Through translational and clinical research, the EORTC offers an integrated approach to drug development, treatment evaluation programs and medical practices across all tumour types. Activities are driven through the EORTC Headquarters based in Brussels, Belgium.


ABOUT ESTRO – European Society for Radiotherapy and Oncology

The European Society for Radiotherapy and Oncology (ESTRO) is an international scientific society with about 7500 individual members worldwide and an important number of corporate members. ESTRO’s mission is to foster radiation oncology in all its aspects.  The society aims at developing standards for radiation oncology, radiation physics, radiation technology and radiobiology, to promote international exchange of scientific information and to provide education and training in these fields.  To set these standards, the Society facilitates research and development in radiotherapy, clinical oncology and related subjects and encourages co-operation with international, regional and national societies and bodies in the field of oncology. By setting standards for education, practice and quality assurance in radiation oncology and associated professions, ESTRO’s long term aim is to improve the standards of cancer treatment for patients in Europe and worldwide.

Back to news list

Related News

  • Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types

  • Publication of 2022 EORTC Annual Report

  • EORTC is supporting Clinical Trials Day on 20th May

  • Studying long-term survivors of glioblastoma may pave the way to better treatment

  • Three new EORTC clinical trials funded by the EU

  • Important new results from EORTC to be presented at ESTRO 2023

  • EORTC QLG proudly collaborates on the EUonQoL project

  • HMP Global and EORTC announce partnership for the 25th annual World Congress on Gastrointestinal Cancer

  • EORTC: Working towards “Closing the Care Gap”

  • First international recommendations on the use of item libraries for patient-reported outcome measurement